 controlled trial foscarnet vidarabine acyclovir-resistant mucocutaneous herpes acquired immunodeficiency syndrome AIDS Clinical Trials Group BACKGROUND AND METHODS strains herpes simplex virus resistant acyclovir susceptible vitro foscarnet vidarabine randomized trial foscarnet vidarabine patients acquired immunodeficiency syndrome AIDS mucocutaneous herpetic lesions unresponsive intravenous therapy acyclovir minimum days patients foscarnet mg kilogram body hours vidarabine mg day days isolates herpes simplex virus vitro resistance susceptibility RESULTS lesions patients days therapy contrast vidarabine failure patients time healing time percent reductions size lesions pain score time end viral patients patients new neurologic abnormalities vidarabine patient foscarnet toxicity initial recurrences herpes simplex infection index lesion susceptible acyclovir-resistant infection healed patient median days range foscarnet CONCLUSIONS treatment acyclovir-resistant herpes simplex infection patients AIDS foscarnet efficacy frequent serious toxicity vidarabine treatment high frequency relapse